Mr. Bill Adams reports

NERVGEN PHARMA GRANTS STOCK OPTIONS

Nervgen Pharma Corp. has granted 600,000 incentive stock options to directors and employees of the company. The options are exercisable at a price of $4 per share. Five hundred thousand of the options were granted to the company's directors, and are exercisable for a period of five years and vest equally every three months over a one-year period. One hundred thousand of the options were granted to employees, and are exercisable for a period of 10 years and vest equally every six months over a four-year period. All options have been granted in accordance with the policies of the TSX Venture Exchange and the conditions of the company's stock option plan.

About Nervgen Pharma Corp.

Nervgen is a clinical-stage biotech company dedicated to developing innovative treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company is testing the clinical efficacy of its lead candidate, NVG-291, in a phase 1b/2a clinical trial in spinal cord injury and has initiated preclinical test of concept evaluation of its pipeline candidate, NVG-300, in models of ischemic stroke and spinal cord injury.